EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma

Ziran Wang, Lingjun Kong, Rui Zhang, Xiaobo Yang, Zhe Cao, Tengda Xu iD, Han Zhang, Yaling Dou

Journal of Hepatocellular Carcinoma · 2024-01 · Volume 11 · 131-143

DOI: 10.2147/jhc.s443006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2024-01. Verfasst von Ziran Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the diagnostic performance of aldo-keto reductase family 1 member B10 (AKR1B10) in a Beijing cohort with hepatocellular carcinoma (HCC).

Methods

This study included 521 subjects who visited Peking Union Medical College Hospital from June 2017 to May 2023, including 109 cases of HCC, 165 cases of healthy controls, 106 cases of benign liver diseases, and 141 cases of other cancers. Serum AKR1B10 levels were measured and compared across various groups. Diagnostic performances of serum AKR1B10 and other tumor markers were assessed using receiver operator characteristic (ROC) curves. In addition, a subset of HCC patients who underwent surgical resection were recruited for clinical follow-up study.

Results

We found that serum AKR1B10 expression was higher in patients with HCC relative to other control groups. The association between serum AKR1B10 and clinical features of HCC was not observed. Serum AKR1B10 showed a high diagnostic performance for HCC, and when combined with AFP, the diagnostic effectiveness was significantly improved. Specifically, serum AKR1B10 showed superior diagnostic effectiveness for AFP-negative HCC. The clinical follow-up study indicated a gradual decrease in serum AKR1B10 after surgery.

Conclusion

Our study demonstrated that serum AKR1B10 is a promising biomarker for HCC, and when used in combination with AFP can significantly improve the detection rate of HCC.

Schlagwörter

Stichwörter der Autor:innen

AFPAKR1B10diagnostic performancehepatocellular carcinoma

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
  • Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
  • Hunan Light of Life Biotechnology Co., Ltd., Ningxiang, Hunan, People's Republic of China.
  • Department of Health Management, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.

ORCID-Profile: Tengda Xu

Zitieren

APA

Wang, Z., Kong, L., Zhang, R., Yang, X., Cao, Z., Xu, T., Zhang, H., & Dou, Y. (2024). Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, Volume 11, 131-143. https://doi.org/10.2147/jhc.s443006

Vancouver

Wang Z, Kong L, Zhang R, Yang X, Cao Z, Xu T, et al. Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2024;Volume 11:131-143. doi:10.2147/jhc.s443006

BibTeX
@article{Wang2024,
  author = {Wang, Ziran and Kong, Lingjun and Zhang, Rui and Yang, Xiaobo and Cao, Zhe and Xu, Tengda and Zhang, Han and Dou, Yaling},
  title = {Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2024},
  volume = {Volume 11},
  pages = {131--143},
  doi = {10.2147/jhc.s443006}
}
Kostenlos starten →